IDH1 and central nervous system cancer: Glioma biomarkers of predictive value for PARPi therapeutic efficacy include IDH1/2 mutations, a low BRCA1 expression, aberrant ATM or ATR signaling, MYC overexpression, and inactivation of mismatch repair genes, especially MSH6 [36,123,189,190,191,192,193,194].